• Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Search
Arvinas Logo
Arvinas logo
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
Search
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
  • Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
07OctOctober 7, 2026

Phase 1 Study of ARV-102, a PROTAC LRRK2 Degrader, in Parkinson’s Disease: Oculomotor and Biomarker Data

07OctOctober 7, 2026

Phase 1 Study of ARV-102, a PROTAC LRRK2 Degrader, in Parkinson’s Disease: Oculomotor and Biomarker Data

28SepSeptember 28, 2026

Phase 1 Study of a PROTAC PolyQ-AR Degrader (ARV-027) in Healthy Participants and Participants With Spinal and Bulbar Muscular Atrophy

13JulJuly 13, 2026

PROTAC LRRK2 Degraders Reduce Pathological Tau and Modulate Endolysosomal–Neuroinflammatory Pathways in Translational Model Systems

03JunJune 3, 2026

ARV-393, a PROTAC BCL6 Degrader, Combined With the CD20×CD3 Bispecific Glofitamab in a Preclinical Model of HGBCL

01JunJune 1, 2026

Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, as Monotherapy in Patients With Advanced NHL or Combined With Glofitamab in Patients With DLBCL

21AprApril 21, 2026

Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, as Monotherapy in Patients With Advanced NHL or Combined With Glofitamab in Patients With DLBCL

21AprApril 21, 2026

Preclinical Antitumor and Immunomodulatory Activity of ARV-6723, a PROTAC HPK1 Degrader, Versus ICIs

21AprApril 21, 2026

Preclinical Efficacy of a PROTAC Pan-KRAS Degrader in a KRAS G12D Syngeneic Mouse Model and Concurrent Immune TME Changes

17MarMarch 17, 2026

Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ARV-102, a PROTAC LRRK2 Degrader, in Participants With Parkinson’s Disease

12Next  
Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
LinkedIn
X

Accessibility Statement

© 2026 Arvinas. All rights reserved.

Arvinas

You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE